Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

N/A

3(42.9%)

Phase 2

3(42.9%)

Phase 3

1(14.3%)

7Total

N/A(3)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05206994Not ApplicableEnrolling By Invitation

Evaluation of the Close to Home Program in California

Role: collaborator

NCT06112834Phase 2Completed

Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®

Role: lead

NCT06747637Not ApplicableRecruiting

Demonstrating the Efficacy of a Spanish-Language Program for Latino Dementia Caregivers

Role: collaborator

NCT05968300Not ApplicableCompleted

Getting INFORMED and Living Well Among Asian Americans in California

Role: collaborator

NCT03676634Phase 2Completed

Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®

Role: lead

NCT01502306Phase 3Completed

A Randomized Trial of Medi-Cal Beneficiaries Calling the California Smokers' Helpline

Role: collaborator

NCT01701999Phase 2Completed

Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid

Role: lead

All 7 trials loaded